Vor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 32,451 Shares

Key Points

• Reprogrammed Interchange LLC, a major shareholder of Vor Biopharma, sold 32,451 shares of the company at an average price of $39.83, totaling approximately $1.29 million, resulting in a 1.98% decrease in their position.
• Vor Biopharma's stock recently experienced a 2.1% increase, reaching $37.46, with a market capitalization of $256.75 million.
• Analysts have primarily rated Vor Biopharma as a moderate buy, with a consensus target price set at around $113.83.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 32,451 shares of the company's stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $39.83, for a total transaction of $1,292,523.33. Following the completion of the sale, the insider directly owned 1,605,209 shares in the company, valued at approximately $63,935,474.47. The trade was a 1.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The shares were sold at an average price of $37.83, for a total transaction of $298,894.83.
• On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The shares were sold at an average price of $39.19, for a total transaction of $54,866.00.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The shares were sold at an average price of $1.54, for a total transaction of $688,808.12.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The shares were sold at an average price of $30.80, for a total transaction of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $32.80, for a total transaction of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The stock was sold at an average price of $35.00, for a total transaction of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 14,240 shares of Vor Biopharma stock. The shares were sold at an average price of $36.60, for a total transaction of $521,184.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The shares were sold at an average price of $39.80, for a total transaction of $924,195.80.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 17,500 shares of Vor Biopharma stock. The shares were sold at an average price of $36.40, for a total transaction of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 22,461 shares of Vor Biopharma stock. The shares were sold at an average price of $40.00, for a total transaction of $898,440.00.

Vor Biopharma Stock Up 2.1%

NYSE:VOR traded up $0.78 on Friday, reaching $37.46. The stock had a trading volume of 390,504 shares, compared to its average volume of 389,991. The company has a market capitalization of $256.75 million, a P/E ratio of -22.70 and a beta of 2.05. Vor Biopharma Inc. has a 1-year low of $2.62 and a 1-year high of $65.80. The stock has a fifty day moving average price of $38.88 and a 200-day moving average price of $24.15.

Institutional Investors Weigh In On Vor Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of VOR. Money Concepts Capital Corp increased its stake in Vor Biopharma by 106.1% in the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after purchasing an additional 26,535 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Vor Biopharma by 218.2% in the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after purchasing an additional 58,247 shares in the last quarter. XTX Topco Ltd bought a new stake in Vor Biopharma in the second quarter valued at approximately $66,000. OMERS ADMINISTRATION Corp bought a new stake in Vor Biopharma in the first quarter valued at approximately $100,000. Finally, Jane Street Group LLC bought a new stake in Vor Biopharma in the first quarter valued at approximately $140,000. 97.29% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

VOR has been the topic of a number of research reports. Stifel Nicolaus upgraded shares of Vor Biopharma from a "hold" rating to a "buy" rating and set a $55.00 target price on the stock in a research report on Wednesday, September 24th. Wedbush reiterated an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Finally, HC Wainwright reissued a "buy" rating and set a $60.00 price target on shares of Vor Biopharma in a research note on Thursday, August 14th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Vor Biopharma has a consensus rating of "Moderate Buy" and an average target price of $113.83.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.